Your account is not claimed yet. You can sign up with ORCID to claim your account.

Marc Maliepaard

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Venues

Pharmacology research & perspectives

Clinical pharmacokinetics

Pharmaceutical medicine

Clinical pharmacology and therapeutics

Medicines Evaluation Board

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Medicines Evaluation Board Feb 1o 2001

Netherlands

Senior Clinical Assessor :: FTK

Publications

Marc Maliepaard, Yoran S Faber, Mark T J van Bussel
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. Pharmacology research & perspectives 11 (2) (2023)
Marc Maliepaard, Yoran S Faber, Mark T J van Bussel
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. Pharmacology research & perspectives 11 (2) (2023)
Audrey M M Hermans, Marc Maliepaard, Wouter P C Boon, Anna Maria Gerdina Pasmooij
Impact of the new European Union In Vitro Diagnostics Regulation on the practice of hospital diagnostic laboratories. Expert review of molecular diagnostics 22 (5) (2022)
Pieter J Glerum, Cees Neef, David M Burger, Yang Yu, Marc Maliepaard
Pharmacokinetics and Generic Drug Switching: A Regulator's View. Clinical pharmacokinetics 59 (9) (2021)
Marc Maliepaard, Timi Toiviainen, Marie Louise De Bruin, Didier Meulendijks
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017. Clinical pharmacology and therapeutics 108 (2) (2020)
Yang Yu, Marc Maliepaard
Comment on "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?" Clinical pharmacokinetics 59 (2) (2020)
Marc Maliepaard, Anne C Taams, Cynthia Sung, Jalene Poh, Yang Yu
Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation? Pharmaceutical medicine 33 (5) (2020)

Marc Maliepaard.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Marc Maliepaard